<?xml version="1.0" ?>
<tei>
	<teiHeader>
		<fileDesc xml:id="55014867"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
<lb/>
	<note type="page">180<lb/></note>

	<div type="abstract">Traditional barriers to large-scale mammalian culture have now<lb/> been addressed, with the standard stirred-tank reactor<lb/> emerging as industry&apos;s technology of choice. The issues of<lb/> adapting cells to suspension culture, shear sensitivity and<lb/> oxygen supply have been largely resolved. But for many low-<lb/>volume and speciality applications, such as the production of<lb/> viral vaccines and gene therapies, reactor technology remains<lb/> diversified, with reactor types ranging from roller bottles to<lb/> stacked plates and hollow fibers.<lb/></div>

	<byline>
	<affiliation>Addresses Bioprocess R&amp;D, Merck Research Laboratories, Merck &amp; Co, Inc,<lb/></affiliation>
	</byline>

	<address>PO Box 2000, Rahway, NJ 07065, USA<lb/></address>

	<email>*e-mail: lily_chu@merck.com<lb/></email>

	<reference>Current Opinion in Biotechnology 2001, 12:180–187<lb/></reference>

	<note>0958-1669/01/$ </note>

	<note type="other">— see front matter<lb/></note>

	<note type="copyright">© 2001 Elsevier Science Ltd. All rights reserved.<lb/></note>

		</front>
	</text>
</tei>
